文献速递白血病

老年急性髓系白血病化疗联合维奈克拉试验(CAVEAT)1b期最终分析

Final analysis of the phase 1b Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT).
PubMed 文献 · Blood Adv · 2025-01-01

CAVEAT 1b期试验在≥65岁新诊断急性髓系白血病患者中,将维奈克拉与强化化疗联合,85例患者中位年龄71岁,中位随访41.8个月。总缓解率75%,中位总生存19.3个月;原发AML亚组总缓解率88%,中位总生存33.1个月。诱导治疗耐受良好,死亡率4%。

要点

  • CAVEAT诱导方案为阿糖胞苷+伊达比星联合5个剂量水平维奈克拉(50-600 mg),最长14天。
  • 总缓解率75%,中位总生存19.3个月(95%CI 11.1-31.3);原发AML总缓解率88%,中位总生存33.1个月(95%CI 19.3-54.3)。
  • 诱导治疗耐受良好,死亡率4%,高级别胃肠道毒性4%;巩固后推迟的血液学恢复可通过去除伊达比星改善。

核心结论

  • CAVEAT诱导方案耐受良好且与高且持久的总体缓解率相关,尤其在原发AML中;CAVEAT代表一种有效的限时治疗选择,适用于体能状况较好的老年AML患者。

研究设计与样本

  • CAVEAT为1b期试验,纳入85例新诊断急性髓系白血病患者,中位年龄71岁(≥65岁),中位随访41.8个月。
  • CAVEAT诱导方案联合阿糖胞苷和伊达比星与5个剂量水平维奈克拉(50-600 mg),最长14天。
  • 另有两个队列探索调整剂量维奈克拉(50 mg和100 mg)联合泊沙康唑。
  • 该试验在https://www.anzctr.org.au注册,注册号为#ACTRN12616000445471。

主要发现

  • CAVEAT诱导治疗耐受良好,死亡率4%,高级别胃肠道毒性4%。
  • 巩固后推迟的血液学恢复通过去除缓解后治疗中的伊达比星得到改善。
  • 总缓解率(完全缓解+部分血液学恢复的完全缓解+计数不完全恢复的完全缓解)为75%,中位总生存19.3个月(95%CI 11.1-31.3)。
  • 在原发AML中,总缓解率为88%,中位总生存为33.1个月(95%CI 19.3-54.3)。
  • 近三分之一患者未复发,许多患者获益于延长的无治疗缓解(中位17.9个月)。

临床怎么用

  • 作者认为CAVEAT代表一种有效的限时治疗选择,适用于体能状况较好的老年AML患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Venetoclax plus azacitidine represents a key advance for older, unfit patients with acute myeloid leukemia (AML). The Chemotherapy and Venetoclax in Elderly AML Trial (CAVEAT) was first to combine venetoclax with intensive chemotherapy in newly diagnosed patients aged ≥65 years. In this final analysis, 85 patients (median age, 71 years) were followed up for a median of 41.8 months. The CAVEAT induction combined cytarabine and idarubicin with 5 dose levels of venetoclax (50-600 mg) for up to 14 days. Two additional cohorts explored adjusted-dose venetoclax (50 mg and 100 mg) with posaconazole. CAVEAT induction was well tolerated, with low mortality (4%) and limited high-grade gastrointestinal toxicity (4%). Delayed hematologic recovery after consolidation was ameliorated by omitting idarubicin from postremission therapy. The overall response rate (ORR; complete response [CR] + CR with partial hematologic recovery + CR with incomplete count recovery) was 75%, with a median overall survival (OS) of 19.3 months (95% confidence interval [CI], 11.1-31.3). Among de novo AML, ORR was 88% and median OS was 33.1 months (95% CI, 19.3-54.3). Almost one-third have not relapsed, many benefiting from prolonged treatment-free remission (median, 17.9 months). CAVEAT induction was well tolerated and associated with high ORR that was durable, particularly for de novo AML. CAVEAT represents an effective time-limited treatment option for fit, older patients with AML. This trial was registered at https://www.anzctr.org.au as #ACTRN12616000445471.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Chua CC, Loo S, Fong CY, et al. Final analysis of the phase 1b Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT). Blood Adv. 2025. PMID: 39825857. doi:10.1182/bloodadvances.2024014900

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。